Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein

被引：49
|
作者：
Zhu, Andrew X. [1 ]
Finn, Richard S. [2 ]
Galle, Peter R. [3 ]
Llovet, Josep M. [4 ,5 ]
Kudo, Masatoshi [6 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[2] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA
[3] Univ Med Ctr, Mainz, Germany
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[5] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain
[6] Kindai Univ, Osaka, Japan
来源：
LANCET ONCOLOGY | 2019年 / 20卷 / 04期
关键词：
D O I：
10.1016/S1470-2045(19)30165-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E191 / E191
页数：1
相关论文
共 50 条
  • [1] Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2
    Kudo, Masatoshi
    Galle, Peter R.
    Llovet, Josep M.
    Finn, Richard S.
    Vogel, Arndt
    Motomura, Kenta
    Assenat, Eric
    Merle, Philippe
    Brandi, Giovanni
    Daniele, Bruno
    Okusaka, Takuji
    Tomasek, Jiri
    Borg, Christophe
    Dadduzio, Vincenzo
    Morimoto, Manabu
    Pracht, Marc
    Jen, Min-Hua
    Drove Ubreva, Nora
    Widau, Ryan C.
    Shinozaki, Kenta
    Yoshikawa, Reigetsu
    Zhu, Andrew X.
    LIVER INTERNATIONAL, 2020, 40 (08) : 2008 - 2020
  • [2] Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)
    Zhu, A. X.
    Galle, P. R.
    Llovet, J. M.
    Finn, R. S.
    Kang, Y-K.
    Yen, C. J.
    Assenat, E.
    Brandi, G.
    Motomura, K.
    Ohno, I.
    Daniele, B.
    Vogel, A.
    Yamashita, T.
    Hsu, C-H.
    Meyer, T.
    Widau, R.
    Schelman, W.
    Wang, C.
    Hsu, Y.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
    Kudo, Masatoshi
    Okusaka, Takuji
    Motomura, Kenta
    Ohno, Izumi
    Morimoto, Manabu
    Seo, Satoru
    Wada, Yoshiyuki
    Sato, Shinpei
    Yamashita, Tatsuya
    Furukawa, Masayuki
    Aramaki, Takeshi
    Nadano, Seijin
    Ohkawa, Kazuyoshi
    Fujii, Hirofumi
    Kudo, Toshihiro
    Furuse, Junji
    Takai, Hiroki
    Homma, Gosuke
    Yoshikawa, Reigetsu
    Zhu, Andrew X.
    JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 627 - 639
  • [4] Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
    Masatoshi Kudo
    Takuji Okusaka
    Kenta Motomura
    Izumi Ohno
    Manabu Morimoto
    Satoru Seo
    Yoshiyuki Wada
    Shinpei Sato
    Tatsuya Yamashita
    Masayuki Furukawa
    Takeshi Aramaki
    Seijin Nadano
    Kazuyoshi Ohkawa
    Hirofumi Fujii
    Toshihiro Kudo
    Junji Furuse
    Hiroki Takai
    Gosuke Homma
    Reigetsu Yoshikawa
    Andrew X. Zhu
    Journal of Gastroenterology, 2020, 55 : 627 - 639
  • [5] Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
    Finn, Richard S.
    Yau, Thomas
    Hsu, Chih-Hung
    De Toni, Enrico N.
    Goyal, Lipika
    Galle, Peter R.
    Qin, ShuKui
    Rao, Sujata
    Sun, Fangfang
    Wang, Chunxiao
    Widau, Ryan C.
    Zhu, Andrew X.
    ONCOLOGIST, 2022, 27 (12): : E938 - E948
  • [6] A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).
    Zhu, Andrew X.
    Galle, Peter R.
    Kudo, Masatoshi
    Finn, Richard S.
    Qin, Shukui
    Xu, Yihuan
    Abada, Paolo
    Llovet, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [7] Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Zhu, Andrew X.
    Kang, Yoon-Koo
    Yen, Chia-Jui
    Finn, Richard S.
    Galle, Peter R.
    Llovet, Josep M.
    Assenat, Eric
    Brandi, Giovanni
    Pracht, Marc
    Lim, Ho Yeong
    Rau, Kun-Ming
    Motomura, Kenta
    Ohno, Izumi
    Merle, Philippe
    Daniele, Bruno
    Shin, Dong Bok
    Gerken, Guido
    Borg, Christophe
    Hiriart, Jean-Baptiste
    Okusaka, Takuji
    Morimoto, Manabu
    Hsu, Yanzhi
    Abada, Paolo B.
    Kudo, Masatoshi
    LANCET ONCOLOGY, 2019, 20 (02): : 282 - 296
  • [8] Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)
    Kudo, Masatoshi
    Finn, Richard S.
    Morimoto, Manabu
    Rau, Kun-Ming
    Ikeda, Masafumi
    Yen, Chia-Jui
    Galle, Peter R.
    Llovet, Josep M.
    Daniele, Bruno
    Lim, Ho Yeong
    McIlwain, David W.
    Yoshikawa, Reigetsu
    Nakamura, Kenichi
    Liang, Kun
    Wang, Chunxiao
    Abada, Paolo
    Widau, Ryan C.
    Zhu, Andrew X.
    LIVER CANCER, 2021, 10 (05) : 451 - 460
  • [9] Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: An expansion cohort of the phase III REACH-2 study
    Finn, R. S.
    Qin, S-K.
    Galle, P. R.
    Wang, C.
    Ogburn, K. D.
    Widau, R.
    Zhu, A. X.
    ANNALS OF ONCOLOGY, 2020, 31 : S702 - S702
  • [10] Ramucirumab for patients with advanced hepatocellular carcinoma and elevated α-fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2
    Finn, Richard S.
    Yau, Thomas
    Hsu, Chih-Hung
    De Toni, Enrico N.
    Goyal, Lipika
    Galle, Peter R.
    Qin, Shukui
    Rao, Sujata
    Sun, Fangfang
    Wang, Chunxiao
    Widau, Ryan C.
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345